本帖最后由 老马 于 2013-3-13 13:43 编辑 5 d) g6 l: D$ e7 X c' ]0 d
1 b u3 Q! u. _% |8 j健择（吉西他滨）+顺铂+阿瓦斯汀5 p/ U* L1 d b; d% ~. Z
Gemzar +Cisplatin + Avastin
; w( K2 \2 k0 m |7 ^http://annonc.oxfordjournals.org/content/21/9/1804.full0 [, B; [% q% E1 @# Z! T& d
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 3 W& j0 L' ]/ [- k
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. # n/ @% R5 q/ x, n1 @" F
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 F4 z- B( w9 S- E4 F' T, _+ p% V
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 806)
3 D$ b% |) @; c! X5 d; u华为网盘附件：
7 R$ n U0 v0 P- V【华为网盘】ava.JPG4 ]# l; [: `3 y6 g
|
显身卡
